Abcellera Biologics Inc
ABCL5.360USD
-0.260-4.63%
Fechamento 10/30, 16:00（ET）Cotações atrasadas em 15 min
1.60BValor de mercado
PerdaP/L TTM
Mais detalhes de Abcellera Biologics Inc Empresa
AbCellera Biologics Inc. discovers and develops antibody medicines for indications across therapeutic areas including cancer, metabolic and endocrine conditions, and autoimmune disorders. The Company’s engine integrates technology, data science, infrastructure, and interdisciplinary teams to solve the antibody discovery problems. The Company has developed technology platforms to unlock drug classes, targets, and modalities, including transmembrane proteins, T-cell engagers, and peptide-MHCs. The Company is focused on advancing an internal pipeline of programs and collaborating on drug development programs with partners. Its first two preclinical programs in its internal pipeline are ABCL575 and ABCL635. ABCL635 is an antibody-drug candidate against an undisclosed target with an indication in metabolic and endocrine conditions. ABCL575 targets OX40 ligand and is being developed as a therapy for the treatment of atopic dermatitis and other indications of autoimmunity and inflammation.
Informações de Abcellera Biologics Inc
Código da empresaABCL
Nome da EmpresaAbcellera Biologics Inc
Data de listagemDec 11, 2020
CEODr. Carl L.G. Hansen, Ph.D.
Número de funcionários596
Tipo de títulosOrdinary Share
Fim do ano fiscalDec 11
Endereço150 W 4Th Avenue
CidadeVANCOUVER
Bolsa de valoresNASDAQ Global Select Consolidated
PaísCanada
Código postalV5Y 1G6
Telefone16045599005
Sitehttps://www.abcellera.com/
Código da empresaABCL
Data de listagemDec 11, 2020
CEODr. Carl L.G. Hansen, Ph.D.
Executivos da empresa Abcellera Biologics Inc
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Veronique Lecault, Ph.D.
Dr. Veronique Lecault, Ph.D.
Co-Founder, Chief Operating Officer, Director
Co-Founder, Chief Operating Officer, Director
9.61M
--
Mr. Andrew Booth
Mr. Andrew Booth
Chief Financial Officer
Chief Financial Officer
283.96K
--
Mr. Tryn T. Stimart, J.D.
Mr. Tryn T. Stimart, J.D.
Chief Legal Officer, Chief Compliance Officer, Corporate Secretary and Privacy Officer
Chief Legal Officer, Chief Compliance Officer, Corporate Secretary and Privacy Officer
--
--
Dr. Andrew W. Lo, Ph.D.
Dr. Andrew W. Lo, Ph.D.
Independent Director
Independent Director
--
--
Mr. John S. Montalbano
Mr. John S. Montalbano
Independent Director
Independent Director
--
--
Dr. Carl L.G. Hansen, Ph.D.
Dr. Carl L.G. Hansen, Ph.D.
Chairman of the Board, President, Chief Executive Officer, Co-Founder
Chairman of the Board, President, Chief Executive Officer, Co-Founder
--
--
Dr. Sarah B. Noonberg, M.D., Ph.D.
Dr. Sarah B. Noonberg, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Michael R. Hayden
Dr. Michael R. Hayden
Lead Independent Director
Lead Independent Director
--
--
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Veronique Lecault, Ph.D.
Dr. Veronique Lecault, Ph.D.
Co-Founder, Chief Operating Officer, Director
Co-Founder, Chief Operating Officer, Director
9.61M
--
Mr. Andrew Booth
Mr. Andrew Booth
Chief Financial Officer
Chief Financial Officer
283.96K
--
Mr. Tryn T. Stimart, J.D.
Mr. Tryn T. Stimart, J.D.
Chief Legal Officer, Chief Compliance Officer, Corporate Secretary and Privacy Officer
Chief Legal Officer, Chief Compliance Officer, Corporate Secretary and Privacy Officer
--
--
Dr. Andrew W. Lo, Ph.D.
Dr. Andrew W. Lo, Ph.D.
Independent Director
Independent Director
--
--
Mr. John S. Montalbano
Mr. John S. Montalbano
Independent Director
Independent Director
--
--
Dr. Carl L.G. Hansen, Ph.D.
Dr. Carl L.G. Hansen, Ph.D.
Chairman of the Board, President, Chief Executive Officer, Co-Founder
Chairman of the Board, President, Chief Executive Officer, Co-Founder
--
--
Detalhamento da receita
Moeda: USDAtualizado em: seg, 6 de out
Moeda: USDAtualizado em: seg, 6 de out
FY2025Q2
FY2024Q2
FY2023Q2
Por EmpresaUSD
Nome
Receita
Proporção
Licensing revenue
10.45M
61.14%
Research fees
6.64M
38.86%
Sem dados
Por Empresa
Por Região
Por EmpresaUSD
Nome
Receita
Proporção
Licensing revenue
10.45M
61.14%
Research fees
6.64M
38.86%
Distribuição de ações
Atualizado em: dom, 12 de out
Atualizado em: dom, 12 de out
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
Thermopylae Holdings Ltd
18.79%
Baker Bros. Advisors LP
9.21%
Capital World Investors
4.47%
Baillie Gifford & Co.
3.47%
Lecault (Veronique)
3.22%
Outro
60.85%
Investidores
Investidores
Proporção
Thermopylae Holdings Ltd
18.79%
Baker Bros. Advisors LP
9.21%
Capital World Investors
4.47%
Baillie Gifford & Co.
3.47%
Lecault (Veronique)
3.22%
Outro
60.85%
Tipos de investidores
Investidores
Proporção
Corporation
18.79%
Hedge Fund
16.22%
Investment Advisor
15.98%
Individual Investor
4.15%
Investment Advisor/Hedge Fund
2.97%
Bank and Trust
1.20%
Private Equity
1.13%
Research Firm
0.62%
Venture Capital
0.32%
Outro
38.61%
Participação acionária institucional
Atualizado em: qua, 1 de out
Atualizado em: qua, 1 de out
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q3
319
114.85M
38.43%
-43.37M
2025Q2
372
214.57M
71.89%
-123.81K
2025Q1
429
202.31M
67.85%
-22.54M
2024Q4
453
194.86M
65.41%
-21.40M
2024Q3
451
190.45M
64.55%
-29.37M
2024Q2
449
195.17M
66.27%
-23.48M
2024Q1
442
202.34M
69.21%
-22.49M
2023Q4
434
206.18M
71.07%
-38.61M
2023Q3
437
216.53M
74.89%
-39.50M
2023Q2
439
222.03M
76.83%
-29.38M
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
Thermopylae Holdings Ltd
56.14M
18.79%
--
--
Apr 01, 2025
Baker Bros. Advisors LP
27.53M
9.21%
--
--
Jun 30, 2025
Capital World Investors
13.36M
4.47%
--
--
Jun 30, 2025
Baillie Gifford & Co.
10.36M
3.47%
-835.83K
-7.47%
Jun 30, 2025
Lecault (Veronique)
9.61M
3.22%
--
--
Apr 01, 2025
Two Sigma Investments, LP
8.18M
2.74%
+2.41M
+41.75%
Jun 30, 2025
UBS Asset Management (Americas) LLC
5.00M
1.67%
-1.61M
-24.41%
Jun 30, 2025
ArrowMark Colorado Holdings, LLC
4.11M
1.37%
--
--
Jun 30, 2025
UBS Asset Management (Switzerland)
3.48M
1.16%
-5.59M
-61.65%
Jun 30, 2025
UBS Switzerland AG
3.43M
1.15%
-1.62M
-32.07%
Jun 30, 2025
Ver Mais
ETFs Relacionados
Atualizado em: qui, 2 de out
Atualizado em: qui, 2 de out
Nome
Proporção
iShares Genomics Immunology and Healthcare ETF
2.11%
Virtus LifeSci Biotech Clinical Trials ETF
1.03%
ProShares Ultra Nasdaq Biotechnology
0.13%
Invesco Nasdaq Biotechnology ETF
0.13%
iShares Biotechnology ETF
0.09%
SPDR S&P International Small Cap ETF
0.08%
Invesco RAFI Developed Mkts ex-US SM ETF
0.03%
Avantis US Small Cap Equity ETF
0.01%
SPDR Portfolio Developed World ex-US ETF
0.01%
Fidelity Nasdaq Composite Index ETF
0.01%
Ver Mais
iShares Genomics Immunology and Healthcare ETF
Proporção2.11%
Virtus LifeSci Biotech Clinical Trials ETF
Proporção1.03%
ProShares Ultra Nasdaq Biotechnology
Proporção0.13%
Invesco Nasdaq Biotechnology ETF
Proporção0.13%
iShares Biotechnology ETF
Proporção0.09%
SPDR S&P International Small Cap ETF
Proporção0.08%
Invesco RAFI Developed Mkts ex-US SM ETF
Proporção0.03%
Avantis US Small Cap Equity ETF
Proporção0.01%
SPDR Portfolio Developed World ex-US ETF
Proporção0.01%
Fidelity Nasdaq Composite Index ETF
Proporção0.01%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Sem dados
Data
Tipo
Proporção
Sem dados
